Want to join the conversation?
Leerink Partners analyst Geoffrey Porges questions $GILD whether there is a stable outlook for HCV revenue on a market-by-market basis from its historic lows. COO Kevin Young says that there will be a gradual decline in new patient starts, but the company will, after copious amounts of testing and diagnoses with the CDC, hit an equilibrium.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)